| Explore a lab test for personalized dosing. |
View online |
|
|
|
|
 |
| Alhemo® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age. |
|
| |
|
Your body.
Your data.
Your dose:
|
| Did you know treatment with Alhemo® includes a lab test that provides personalized dosing? |
| Want to learn more information about the lab test and how to prepare? |
|
|
|
|
|
|
|
|
|
Alhemo® has a test that measures the amount of concizumab-mtci in your blood. This allows your healthcare provider to prescribe the dose that fits your body's needs.
|
|
|
| |
|
Day 1
|
-
You will inject a larger dose (a loading dose) of Alhemo® on your first day of treatment
-
Your dose will be based on your weight: 1 mg/kg
|
|
Day 2+
|
-
Your dose will now be 0.2 mg/kg 1 time per day until you take a blood test
|
|
Day 28 (4 weeks after starting Alhemo®)
|
-
To determine the right maintenance dose, you will take the blood test, which will show how much Alhemo® is in your bodya
-
Your healthcare provider may do additional blood tests during treatment with Alhemo®
-
Wait until after the blood draw to take your daily dose of Alhemo® on the day of your test
|
|
aShould be performed before administering next scheduled dose.
|
|
|
|
Needles provided separately and may require a prescription in some states. A new needle is required for each injection.
|
|
|
|
|
| |
|
It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding, especially during the first 4 weeks of treatment, to help establish your maintenance dose.
|
|
|
|
If you miss a dose during the first 4 weeks of treatment, contact your healthcare provider right away. Your healthcare provider will tell you how much Alhemo® to inject.
|
|
|
|
|
If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding.
|
|
| Keep scrolling to learn more about Alhemo® |
 |
|
| Important Safety Information for Alhemo® |
| What is the most important information I should know about Alhemo®? |
| |
• |
It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding |
| |
• |
Your HCP may prescribe factor VIII, factor IX, or bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand factor VIII, factor IX, or bypassing agents and the recommended dose and schedule for breakthrough bleeds |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
| Choosing a treatment doesn’t need to be a headache—you’ve got backup! Meet your Novo Nordisk Rare Blood Community Liaison (RBCL). |
|
RBCLs are dedicated to the hemophilia community with decades of experience providing support and resources. This includes a shared decision-making guide to prepare you for a conversation with your doctor about Alhemo®, assistance with NovoCare® support programs, and other tools to help you manage your bleeding disorder.
|
|
Have you connected with your local RBCL yet? What are you waiting for?
|
|
|
| You can also learn more about NovoCare® by calling 1-844-668-6732 or visiting NovoCare.com |
|
|
|
 |
| Stay in the know |
| Be the first to get important updates about Alhemo®, including patient support programs, insurance information through NovoCare®, and more. |
|
|
|
| What is Alhemo® |
| Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. |
| |
• |
It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age |
|
| Important Safety Information (cont’d) |
| Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®. |
| Before using Alhemo®, tell your HCP about all of your medical conditions, including if you: |
| |
• |
Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery |
| |
• |
Are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk |
|
| |
| |
◦ |
Your HCP may do a pregnancy test before you start treatment with Alhemo®. |
| |
◦ |
Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment |
|
|
| Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements. |
| What are the possible side effects of Alhemo®? |
| Alhemo® may cause serious side effects, including: |
| |
• |
Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision |
| |
• |
Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat |
|
| The most common side effects of Alhemo® include: bruising, redness, bleeding, itching, rash or lump at the injection site, headache, and hives. These are not all the possible side effects of Alhemo®. Call your doctor for medical advice about side effects. |
| Please see Prescribing Information and Medication Guide for Alhemo®. |
| Alhemo® is a prescription medication. |
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Alhemo® is a registered trademark of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2026 Novo Nordisk All rights reserved. US25AHM00428 February 2026 |
 |
|
|
|
